First in Class Bispecific Next Generation ADC targeting EGFR/ROR1 to progress into pre-clinical development
Almac Discovery, a research driven drug discovery company and member of the Almac Group, has announced the nomination of a new pre-clinical candidate molecule (ALM-401), a First in Class Bispecific Antibody Drug Conjugate (ADC) for the treatment of refractory lung...
2024 Impact Report: The Scottish National Investment Bank helps Elasmogen to develop next-generation therapeutic drugs
https://www.youtube.com/watch?v=YpcwHA7GG0w Hear from Elasmogen's CEO, Prof. Caroline Barelle, how The Scottish National Investment Bank helps to develop next-generation therapeutic drugs, with the potential to improve the health of people in Scotland and globally.
Harlaw Academy students visited Elasmogen
On 13th of November, as part of the Excelerate program, advanced higher biology students from Harlaw Academy visited Elasmogen. The students participated in interactive theory and practical sessions learning from Elasmogen’s scientists about fundamental ELISA and PCR...
Elasmogen has been announced as a finalist for the Deal & Dealmakers Awards
Insider.co.uk has announced today the shortlist for the Deal & Dealmakers Awards. Elasmogen is nominated for Early Stage Deal of the Year in partnership with RBC Brewin Dolphin. Please see here the link to the story.
Elasmogen team took a part in the regional event hosted by the BIA in collaboration with ONE
On 10th of May Elasmogen team took part in the regional event hosted by the BIA in collaboration with opportunity North East. The event took place at the new BioHub. Our principal scientist and program lead Dr Obinna Ubah was in the panel along with other life science...
Dr Jane Dancer named as the new Chair of Elasmogen Ltd
Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board. Jane joined Elasmogen as a non-executive director in April 2022 on the back of new investment from BGF, The Bank and Scottish Enterprise who joined existing investors, Deepbridge...
Elasmogen and Intract Enter License Agreement for Soteria® and Phloral® Technologies
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen exclusive access to Soteria® and Phloral® technologies for oral colonic delivery of therapeutic...
BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen
Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The...
Shark antibody-like proteins neutralize COVID-19 virus, help prepare for future coronaviruses
MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16. The new...